AMEX · Drug Manufacturers - General

SRXH (SRXH) Stock

$1.48 +2.07% AMEX: SRXH Healthcare

Valuation

MetricValue
Price$1.48
Market Cap$14.56M
P/E Ratio-0.01
P/B Ratio0.50
P/S Ratio-0.59
EPS (TTM)$-2.13
52-Week High$4.90
52-Week Low$0.08
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE875.03%
ROA-118.56%
ROCE-12.35%
Gross Margin-157.14%
Operating Margin-171.43%
Net Margin168.61%
Debt/Equity1.24
Current Ratio2.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$46.0M$93.0M$119.0M$35.0M$7.0M
Operating Profit$-17.0M$-1.0M$-6.0M$-6.0M$-12.0M
Net Profit$3.0M$-2.0M$-11.0M$0$-45.0M
EPS$6.00$-3.48$-0.90$-0.10$-2.13
Op Margin-37.6%-1.3%-4.9%-17.1%-176.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$77.0M$35.0M$65.0M$16.0M$8.0M
Total Liabilities$20.0M$34.0M$71.0M$7.0M$8.0M
Cash$29.0M$2.0M$2.0M$3.0M$1.0M
Borrowings$10.0M$18.0M$39.0M$45.0M$4.0M

Latest News

SRX Global Regains Compliance With NYSE American Listing Requirements MT Newswires · Jul 16, 2026 SRX Global Regains Full Compliance with NYSE American Listing Standards GlobeNewswire · Jul 16, 2026 SRXH Stock Falls Premarket Ahead Of Eric Jackson's Fireside Chat — Traders Brace For Buyback Clues And CEO Spotlight Stocktwits · Jul 14, 2026 SRX Global Management Team to Host Virtual Fireside Chat on July 14, 2026, and Issues Letter to Shareholders GlobeNewswire · Jul 10, 2026 SRX Global Approves $20 Million Stock Buyback Program MT Newswires · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$3.0M$3.0M$-4.0M$-8.0M
Investing Cash Flow$-1.0M$-7.0M$-21.0M$-2.0M$6.0M
Financing Cash Flow$-2.0M$0$5.0M$0$0
Net Cash Flow$25.0M$2.0M$1.0M$-1.0M$-2.0M
Free Cash Flow$-12.0M$3.0M$2.0M$-4.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.41
FCF Yield22.66%
Quick Ratio1.64
Interest Coverage-0.38
Return 1Y-92.97%
Return 3Y-99.44%
Return 5Y-99.97%

Ownership

Insiders Held1.97%
Institutions Held0.73%
Institutions Float Held0.74%
Institutional HolderSharesReport Date
Jane Street Group, LLC9,9212026-03-31
Geode Capital Management, LLC4,1252026-03-31
Two Sigma Securities, LLC3,2542026-03-31
Scotia Capital Inc.1,8022026-03-31
UBS Group AG1,4292026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AEONAEON Biopharma, Inc. $0.24 -5.50% -0.05 $2.80M 0.00%
BOLT $3.95 -0.50% -0.26 $7.59M 0.00%
CLRB $2.37 -2.07% -0.38 $7.57M 0.00%
GELS $0.62 -6.94% — $5.65M 0.00%
MRKR $1.19 -2.46% -1.80 $12.85M 0.00%

About SRXH

SRXH is led by CEO Kent Cunningham, employs 11 people, headquartered in US, publicly traded since 2010.

SRXH stock trades at $1.48 with a market capitalization of $14.56M. The stock is valued at a price-to-earnings (P/E) ratio of -0.01, price-to-book of 0.50, price-to-sales of -0.59. Over the past 52 weeks the stock has ranged between $0.08 and $4.90, and currently trades 69.8% below its 52-week high.

On profitability, SRXH generates a return on equity (ROE) of 875.03% — well above the market average, a sign of a high-quality business, return on capital employed of -12.35%, an operating margin of -171.43%, a net profit margin of 168.61%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides